PL2515870T3 - Miejscowa oftalmiczna formulacja peptydowa - Google Patents

Miejscowa oftalmiczna formulacja peptydowa

Info

Publication number
PL2515870T3
PL2515870T3 PL10810911.7T PL10810911T PL2515870T3 PL 2515870 T3 PL2515870 T3 PL 2515870T3 PL 10810911 T PL10810911 T PL 10810911T PL 2515870 T3 PL2515870 T3 PL 2515870T3
Authority
PL
Poland
Prior art keywords
topical ophthalmic
peptide formulation
ophthalmic peptide
formulation
topical
Prior art date
Application number
PL10810911.7T
Other languages
English (en)
Inventor
Canonge Rafael Simó
Pascual Cristina Hernández
Carneado Jimena Fernández
Caminals Marc Gómez
I Lluch Ribera Jordana
Sinfreu Josep Farrera
Obiols Berta Ponsati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43928893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2515870(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL2515870T3 publication Critical patent/PL2515870T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10810911.7T 2009-12-22 2010-12-17 Miejscowa oftalmiczna formulacja peptydowa PL2515870T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200931242A ES2362604B1 (es) 2009-12-22 2009-12-22 Formulación tópica oftálmica de péptidos.

Publications (1)

Publication Number Publication Date
PL2515870T3 true PL2515870T3 (pl) 2016-11-30

Family

ID=43928893

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10810911.7T PL2515870T3 (pl) 2009-12-22 2010-12-17 Miejscowa oftalmiczna formulacja peptydowa

Country Status (34)

Country Link
US (1) US9216208B2 (pl)
EP (1) EP2515870B1 (pl)
JP (1) JP5920928B2 (pl)
KR (1) KR101657737B1 (pl)
CN (1) CN102753153B (pl)
AR (1) AR079683A1 (pl)
AU (1) AU2010335595B2 (pl)
BR (1) BR112012015386B8 (pl)
CA (1) CA2785104C (pl)
CL (1) CL2012001737A1 (pl)
CO (1) CO6592047A2 (pl)
CY (1) CY1117854T1 (pl)
DK (1) DK2515870T3 (pl)
ES (2) ES2362604B1 (pl)
HR (1) HRP20160954T1 (pl)
HU (1) HUE028193T2 (pl)
IL (1) IL220584A (pl)
LT (1) LT2515870T (pl)
MX (1) MX338323B (pl)
MY (1) MY178169A (pl)
NZ (1) NZ600627A (pl)
PH (1) PH12012501271A1 (pl)
PL (1) PL2515870T3 (pl)
PT (1) PT2515870T (pl)
RS (1) RS54953B1 (pl)
RU (1) RU2561585C2 (pl)
SG (1) SG181727A1 (pl)
SI (1) SI2515870T1 (pl)
SM (1) SMT201600277B (pl)
TW (1) TWI548416B (pl)
UA (1) UA108484C2 (pl)
UY (1) UY33153A (pl)
WO (1) WO2011076368A2 (pl)
ZA (1) ZA201204522B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6368722B2 (ja) 2013-03-01 2018-08-01 フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド
GB201516066D0 (en) * 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途
MX390707B (es) 2017-01-31 2025-03-21 Kimberly Clark Co Composición antibacteriana que incluye un éster del ácido benzoico y métodos de inhibición del crecimiento bacteriano mediante el uso de la misma.
CN110678194B (zh) * 2017-05-15 2024-08-06 太阳制药有限公司 奥曲肽注射液
WO2021101344A1 (ko) * 2019-11-21 2021-05-27 삼진제약주식회사 안질환 예방 또는 치료용 점안 조성물
KR102741835B1 (ko) * 2022-03-11 2024-12-12 한국한의약진흥원 등검은말벌독에 함유된 세로토닌의 안정성을 유지하기 위한 조성물
CN120131956A (zh) * 2023-12-11 2025-06-13 中山大学中山眼科中心 生长激素抑制剂的用途、和含有生长激素抑制剂的药物组合物、制剂、及其装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
CN1244794A (zh) 1997-11-06 2000-02-16 奥尔班公司 用于药物释放的稳定的干燥药物组合物及其制备方法
CA2263042A1 (en) * 1999-02-25 2000-08-25 Robert W.A. Kuijpers Treatment of edema
EP1040837A3 (en) * 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
WO2002009739A1 (en) 2000-07-27 2002-02-07 Novartis Ag Treatment of ocular disorders with somatostatin analogues
TWI260228B (en) * 2002-12-31 2006-08-21 Ind Tech Res Inst Delivery carrier of presenting cell of somatostatin receptor
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
AU2004259208B2 (en) 2003-07-15 2011-04-28 Evonik Corporation Method for the preparation of controlled release formulations
US20070082841A1 (en) * 2005-09-27 2007-04-12 Aciont, Inc. Ocular administration of immunosuppressive agents
JP2011505335A (ja) * 2007-09-11 2011-02-24 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのTRP−6−トリプトレリンおよびD−Leu6−ロイプロリドの使用
ES2528409T3 (es) 2007-10-24 2015-02-10 Camurus Ab Formulaciones de liberación controlada

Also Published As

Publication number Publication date
MX2012007282A (es) 2012-10-15
CN102753153A (zh) 2012-10-24
HK1178049A1 (zh) 2013-09-06
CA2785104C (en) 2016-11-01
EP2515870B1 (en) 2016-05-25
TWI548416B (zh) 2016-09-11
JP5920928B2 (ja) 2016-05-18
BR112012015386A2 (pt) 2018-07-24
WO2011076368A2 (en) 2011-06-30
SG181727A1 (en) 2012-07-30
HUE028193T2 (en) 2016-12-28
BR112012015386B1 (pt) 2021-02-23
PT2515870T (pt) 2016-08-29
CL2012001737A1 (es) 2012-11-16
CN102753153B (zh) 2015-11-25
MY178169A (en) 2020-10-06
EP2515870A2 (en) 2012-10-31
SMT201600277B (it) 2016-11-10
ES2362604B1 (es) 2012-06-28
CY1117854T1 (el) 2017-05-17
TW201141514A (en) 2011-12-01
KR101657737B1 (ko) 2016-09-19
RS54953B1 (sr) 2016-11-30
MX338323B (es) 2016-04-12
SI2515870T1 (sl) 2016-09-30
IL220584A0 (en) 2012-08-30
NZ600627A (en) 2014-08-29
UA108484C2 (en) 2015-05-12
ZA201204522B (en) 2013-09-25
US9216208B2 (en) 2015-12-22
AU2010335595A1 (en) 2012-07-12
CO6592047A2 (es) 2013-01-02
JP2013515687A (ja) 2013-05-09
LT2515870T (lt) 2016-10-10
RU2561585C2 (ru) 2015-08-27
CA2785104A1 (en) 2011-06-30
WO2011076368A3 (en) 2012-03-15
UY33153A (es) 2011-06-30
AU2010335595B2 (en) 2015-08-27
ES2362604A1 (es) 2011-07-08
BR112012015386B8 (pt) 2021-05-25
HRP20160954T1 (hr) 2016-10-07
DK2515870T3 (en) 2016-09-05
US20130210728A1 (en) 2013-08-15
RU2012126028A (ru) 2014-01-27
IL220584A (en) 2016-10-31
KR20120120255A (ko) 2012-11-01
AR079683A1 (es) 2012-02-15
PH12012501271A1 (en) 2012-11-05
ES2587828T3 (es) 2016-10-27

Similar Documents

Publication Publication Date Title
IL245328B (en) A pharmaceutical preparation containing carbatocin
ZA201304514B (en) Topical localized isoxazoline formulation
ZA201200719B (en) Pharmaceutical formulation
EP2659911A4 (en) AQUEOUS OPHTHALMIC COMPOSITION
ZA201305591B (en) Fluorocarbon-linked peptide formulation
EP2566487A4 (en) OPHTHALMIC COMPOSITION
PL2496596T3 (pl) Peptydy terapeutyczne
GB0921686D0 (en) Topical formulation
GB0912239D0 (en) Cosmetic formulation
EP2605786A4 (en) THERAPEUTIC PEPTIDES
IL220584A0 (en) Topical ophthalmic peptide formulation
GB0907003D0 (en) Formulation
WO2010114629A9 (en) Formulation
GB0908515D0 (en) Peptide
ZA201203722B (en) Peptide
GB0911213D0 (en) Formulation
GB0907410D0 (en) Formulation
GB201018773D0 (en) Topical pharmaceutical formulation
GB0918286D0 (en) Topical formulations
GB0918285D0 (en) Topical formulations
GB201013824D0 (en) Ophthalmic formulations
GB201007358D0 (en) Conjugated protein C
GB0902472D0 (en) Formulation
GB0906291D0 (en) Formulation
GB0914356D0 (en) Ophthalmic formulations